Loading cancer entity…
Loading cancer entity…
Clinical trials
972 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (145)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05977673 | Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy(FIL_Tisle-HL) | recruiting | Phase 2 | 28 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03843294 | Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma | active not recruiting | Phase 1 | 18 | Catherine BollardOTHER | 1 | Aug 14, 2026 |
| clinicaltrials |
| NCT04537871 | Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study | active not recruiting | — | 350 | City of Hope Medical CenterOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07451054 | CD45BE-HSPC + CART-45 Cells | recruiting | Phase 1 | 42 | University of PennsylvaniaOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05092451 | Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances | recruiting | Phase 1 / Phase 2 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT02861417 | Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant | active not recruiting | Phase 2 | 204 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06090864 | ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells | recruiting | Phase 1 / Phase 2 | 31 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT03907488 | Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma | active not recruiting | Phase 3 | 994 | National Cancer Institute (NCI)NIH | 3 | Aug 4, 2026 | clinicaltrials |
| NCT07259304 | Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors | active not recruiting | — | 118 | University of Southern CaliforniaOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT02727803 | Personalized NK Cell Therapy in CBT | recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT02166463 | Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma | active not recruiting | Phase 3 | 600 | National Cancer Institute (NCI)NIH | 3 | Jul 29, 2026 | clinicaltrials |
| NCT02506933 | Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant | active not recruiting | Phase 2 | 102 | City of Hope Medical CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT05362773 | A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | active not recruiting | Phase 1 | 130 | MacroGenicsINDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT06150664 | A Phase 1 of CTX-8371 in Patients With Advanced Malignancies | recruiting | Phase 1 | 85 | Compass TherapeuticsINDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07020533 | A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant | recruiting | Phase 1 | 46 | City of Hope Medical CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07729397 | Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)(ANCILE-30) | not yet recruiting | Phase 1 | 21 | The Methodist Hospital Research InstituteOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT05346809 | Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma | active not recruiting | Phase 2 | 8 | Divaya BhutaniOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT03739502 | A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant(HBO-UBC) | active not recruiting | Phase 2 | 64 | University of RochesterOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT06176690 | Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas(CABAL2) | recruiting | Phase 1 | 90 | Baylor College of MedicineOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT00923442 | Biology Studies of Hematologic Cancers | enrolling by invitation | — | 550 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07164469 | Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma | not yet recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06580002 | Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial | recruiting | Phase 2 | 75 | University of California, IrvineOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06164275 | Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma | active not recruiting | Phase 2 | 30 | Northwestern UniversityOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT04685616 | Brentuximab Vedotin in Early Stage Hodgkin Lymphoma(RADAR) | recruiting | Phase 3 | 1,042 | University College, LondonOTHER | 12 | Jul 8, 2026 | clinicaltrials |
| NCT04799275 | Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma | active not recruiting | Phase 2 / Phase 3 | 422 | National Cancer Institute (NCI)NIH | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07572123 | Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma | not yet recruiting | Phase 2 / Phase 3 | 374 | National Cancer Institute (NCI)NIH | 0 | Jul 8, 2026 | clinicaltrials |
| NCT01351545 | A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) | recruiting | — | 99,999 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Jul 6, 2026 | clinicaltrials |
| NCT02332668 | A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) | recruiting | Phase 1 / Phase 2 | 370 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Jul 6, 2026 | clinicaltrials |
| NCT04664179 | EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma(CILESTE) | recruiting | Phase 1 | 52 | Baylor College of MedicineOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT03697408 | Itacitinib + Everolimus in Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 23 | University of PennsylvaniaOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04510636 | Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma | recruiting | Phase 2 | 40 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07652476 | Neurocognitive Assessment in Long-Term Survivors of Lymphoma(FIL_LymDeCo) | not yet recruiting | — | 100 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT00840047 | Methionine PET/CT Studies In Patients With Cancer | active not recruiting | Phase 2 | 503 | St. Jude Children's Research HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT02256137 | A Longitudinal Assessment of Frailty in Young Adult Survivors of Childhood Cancer | active not recruiting | — | 1,564 | St. Jude Children's Research HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT03050268 | Familial Investigations of Childhood Cancer Predisposition(SJFAMILY) | recruiting | — | 1,500 | St. Jude Children's Research HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT03361020 | Obstructive Sleep Apnea in Survivors of Hodgkin Lymphoma Treated With Thoracic Radiation | active not recruiting | — | 434 | St. Jude Children's Research HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT03755804 | Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 | active not recruiting | Phase 2 | 232 | St. Jude Children's Research HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT03681561 | Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 54 | Veronika BachanovaOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03622788 | Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07641010 | PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma | not yet recruiting | Phase 1 / Phase 2 | 112 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT02917083 | CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)(RELY-30) | recruiting | Phase 1 | 60 | Baylor College of MedicineOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07222345 | Feasibility of High Intensity Interval Training in Survivors of Childhood, Adolescent, and Young Adult Hodgkin Lymphoma | recruiting | N/A | 20 | St. Jude Children's Research HospitalOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT02663297 | Administration of T Lymphocytes for Prevention of Relapse of Lymphomas | active not recruiting | Phase 1 | 18 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT05723055 | Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma(NAHL) | active not recruiting | Phase 2 | 9 | University of UtahOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT05800210 | Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases | recruiting | Phase 2 | 20 | University of FloridaOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06131801 | Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution | recruiting | — | 30 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05162976 | CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed | active not recruiting | Phase 1 | 33 | City of Hope Medical CenterOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07623850 | A Phase I Study of JLM019 Injection(JLM019) | recruiting | Phase 1 | 115 | Jecho Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT04195633 | Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies | recruiting | Phase 2 | 60 | Fred Hutchinson Cancer CenterOTHER | 1 | May 29, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 19, 2026source: clinicaltrials